AstraZeneca's ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by AstraZeneca in the DESTINY-Endometrial01 phase 3 trial. AstraZeneca is jointly developing and commercializing ENHERTU, which is the drug being evaluated in the DESTINY-Endometrial01 phase 3 trial, with Daiichi Sankyo under a global collaboration.

The study is evaluating ENHERTU (trastuzumab deruxtecan) as a first-line therapy for patients with HER2-expressing (IHC 3+/2+), mismatch repair proficient (pMMR) primary advanced (stage III/IV) or first recurrent endometrial cancer of any histologic subtype except sarcoma. The trial will assess ENHERTU (at a dose of 5.4 mg/kg) in combination with either rilvegostomig or pembrolizumab, compared to the current standard of care, platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab.

Endometrial cancer is the second most common gynecologic cancer and the sixth most common cancer among women globally. In 2022, ~420,000 cases were diagnosed, which led to ~97,000 deaths worldwide. Incidence and mortality rates are projected to increase by ~61% and 87%, respectively, by 2050. The new phase 3 trial aims to further understand ENHERTU’s role in combination with immunotherapy as a potential first-line treatment strategy.

AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. It serves primary and specialty care physicians through distributors and local representative offices in the UK, the US, Europe, and Asia.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.